ViroGates ASOCSE:VIRO 44 EBITDA Margin % is -219.72% as of Mar. 2026. GuruFocus rates OCSE:VIRO with a GF Score™ of 44/100 and a GF Value™ of kr6.80 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, ViroGates AS ranks worse than 84.93% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. ViroGates AS's EBITDA for the
three
months ended in Mar. 2026 was kr-2.86 Mil. ViroGates AS's Revenue for the
three
months ended in Mar. 2026 was kr1.30 Mil. Therefore, ViroGates AS's EBITDA margin for the quarter that ended in Mar. 2026 was -219.72%.
ViroGates AS (OCSE:VIRO) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
ViroGates AS EBITDA Margin % Related Terms
ViroGates AS EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for ViroGates AS's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:VIRO vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, ViroGates AS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ViroGates AS EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ViroGates AS's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where ViroGates AS's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ViroGates AS (OCSE:VIRO) has a EBITDA Margin % of -219.72% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ViroGates AS and its competitors. According to the industry distribution chart, ViroGates AS ranks #693 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 84.9%.
Is ViroGates AS's EBITDA Margin % too high?
ViroGates AS's current EBITDA Margin % is -219.72%. Based on the distribution chart, ViroGates AS ranks #693 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, ViroGates AS has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ViroGates AS's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ViroGates AS ranks #693 out of 816 companies for EBITDA Margin %. This places ViroGates AS in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ViroGates AS and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ViroGates AS's current EBITDA Margin % is -219.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViroGates AS stock overvalued right now?
Based on GuruFocus' analysis, ViroGates AS (OCSE:VIRO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr6.80, compared to a current price of kr10.20 — trading 50% above its estimated fair value. The current EBITDA Margin % is -219.72%. ViroGates AS's overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For ViroGates AS (OCSE:VIRO), the current EBITDA Margin % is -219.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ViroGates AS (OCSE:VIRO) Overvalued in 2026?
Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued.
The current stock price of kr10.20 is trading 50% above its estimated GF Value™ of kr6.80.
GuruFocus considers ViroGates AS to be Significantly Overvalued.
Key valuation signals for OCSE:VIRO:
EBITDA Margin %: -219.72%
GF Value™: kr6.80 vs. price of kr10.20 (50% above fair value)
No single metric tells the full story. See the OCSE:VIRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
44GF Score
Get the complete analysis for OCSE:VIRO
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:VIRO has been successfully added to your 
